Merck (MRK) and Novocure (NVCR) have entered into a clinical trial collaboration agreement to develop Tumor Treating Fields together with Merck’s anti-PD-1 therapy …
The name of the game is growth; that’s what investors are looking for. Growth ensures profits, profits boost share prices, and higher share …
Novocure Ltd (NASDAQ:NVCR) shares were on a close to 40% surge Monday, after the device maker announced positive survival data from a phase 2 pilot trial …
Healthcare stocks Palatin Technologies (NYSEMKT:PTN), Novocure Ltd (NASDAQ:NVCR), and AveXis Inc (NASDAQ:AVXS) are reaping the benefits of clinical and corporate progress updates that have sent the …
Novocure Ltd (NASDAQ:NVCR) announced new Phase 3 data showing that glioblastoma patients who received TTFields in combination with chemotherapy at first recurrence lived …
